745055-91-8

UBP 302 is an antagonist of glutamate receptor 5 (GluR5) subunit-containing kainate receptors that inhibits kainate-induced responses in isolated rat dorsal roots (K_d = 402 nM). In vitro, UBP 302 inhibits gamma frequency oscillations in the rat basolateral amygdala at a concentration of 25 μM, and blocks kainate receptor signaling in layer III neurons within the mouse medial entorhinal cortex at 20 μM, abrogating the intense synaptic activity characteristic of the Up state of cortical slow oscillation. In vivo, UBP 302 (250 mg/kg) significantly reduces seizure severity in a rat model of soman-induced status epilepticus.

UBP 302 is a potent and selective GLUK5 receptor antagonist.

Selective and potent GLU K5 (GluR5)-subunit containing kainate receptor antagonist (apparent K D = 402 nM); active enantiomer of UBP 296 ((RS)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione ). Displays ~ 260-fold selectivity over AMPA receptors. UBP 296 displays ~ 90-fold selectivity over recombinant human GLU K6 - and GLU K2 -containing kainate receptors, has little or no action at NMDA or group I mGlu receptors and selectively blocks kainate receptor-mediated LTP induction in rat hippocampal mossy fibres.

Room temperature

[1] JULIA C.A. MORE . Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist[J]. Neuropharmacology, 2004, 47 1: Pages 46-64. DOI: 10.1016/j.neuropharm.2004.03.005
[2] FIONA E. RANDALL  Mark O C  Miles A Whittington. Fast oscillatory activity induced by kainate receptor activation in the rat basolateral amygdala in vitro[J]. European Journal of Neuroscience, 2011, 33 5: 914-922. DOI: 10.1111/j.1460-9568.2010.07582.x
[3] RICHARD J. DIGBY . Distinct mechanisms of Up state maintenance in the medial entorhinal cortex and neocortex[J]. Neuropharmacology, 2017, 113: Pages 543-555. DOI: 10.1016/j.neuropharm.2016.11.009
[4] STEVEN L. MILLER . A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists[J]. Toxicology and applied pharmacology, 2015, 284 2: Pages 204-216. DOI: 10.1016/j.taap.2015.02.008